COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Two cyclooxygenase isozymes, COX-1 and -2, are known to catalyze the rate-limiting step of prostaglandin synthesis and are the targets of nonsteroidal antiinflammatory drugs. Here we describe a third distinct COX isozyme, COX-3, as well as two smaller COX-1-derived proteins ( p artial COX-1 or PCOX-1 proteins). COX-3 and one of the PCOX-1 proteins (PCOX-1a) are made from the COX-1 gene but retain intron 1 in their mRNAs. PCOX-1 proteins additionally contain an in-frame deletion of exons 5–8 of the COX-1 mRNA. COX-3 and PCOX mRNAs are expressed in canine cerebral cortex and in lesser amounts in other tissues analyzed. In human, COX-3 mRNA is expressed as an ≈5.2-kb transcript and is most abundant in cerebral cortex and heart. Intron 1 is conserved in length and in sequence in mammalian COX-1 genes. This intron contains an ORF that introduces an insertion of 30–34 aa, depending on the mammalian species, into the hydrophobic signal peptide that directs COX-1 into the lumen of the endoplasmic reticulum and nuclear envelope. COX-3 and PCOX-1a are expressed efficiently in insect cells as membrane-bound proteins. The signal peptide is not cleaved from either protein and both proteins are glycosylated. COX-3, but not PCOX-1a, possesses glycosylation-dependent cyclooxygenase activity. Comparison of canine COX-3 activity with murine COX-1 and -2 demonstrates that this enzyme is selectively inhibited by analgesic/antipyretic drugs such as acetaminophen, phenacetin, antipyrine, and dipyrone, and is potently inhibited by some nonsteroidal antiinflammatory drugs. Thus, inhibition of COX-3 could represent a primary central mechanism by which these drugs decrease pain and possibly fever.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although subsequent studies largely failed to confirm a clinically relevant role for COX-3 in humans, the concept stimulated broader exploration of central nervous system (CNS) mechanisms underlying paracetamol-induced analgesia [ 26 ].”
From Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management (2026) · cites this paper as [26]
In the citing paper
“Early investigations, including work by Flower and Vane in the early 1970’s suggested that paracetamol exerted its effects through central inhibition of prostaglandin synthesis, leading to the proposal of a putative COX-3 isoform as a specific molecular target.”
From Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management (2026) · cites this paper as [26]
In the citing paper
“a splice variant of COX-1, derived from the same gene, was characterized in dog brain which was sensitive to inhibition with paracetamol (48); it was designated COX-3 (48)”
From Paracetamol: New Vistas of an Old Drug (2006) · cites this paper as [48]
In the citing paper
“Paracetamol showed selectivity for inhibition of COX-3 (IC 50 = 460 µM) over COX-1 and COX-2, which was dependent on the concentration of the substrate arachidonic acid suggesting competitive blockage at the active site [36].”
From Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action (2021) · cites this paper as [36]
In the citing paper
“Indeed, in 2002 a catalytically functional third COX enzyme was identified and was originally referred to as COX-3 by Professor Daniel Simmons's laboratory [36] and was referred to COX-1b in some publications [37][38][39][40].”
From Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action (2021) · cites this paper as [36]
Citations
Cites
Xie, W. L., Chipman, J. G., Robertson, D. L., Erikson, R. L., & Simmons, D. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.7.2692 · Cited by 1,707
Self-citationWarner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A., & Vane, J. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7563 · Cited by 1,519
Pharmacological analysis of cyclooxygenase-1 in inflammation
Smith, C. J., Zhang, Y., Koboldt, C. M., Muhammad, J., Zweifel, B. S., Shaffer, A., Talley, J. J., Masferrer, J. L., Seibert, K., & Isakson, P. C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13313 · Cited by 807
FLOWER, R. J., & VANE, J. R. (1972) · Nature · doi:10.1038/240410a0 · Cited by 779
Expression of mRNA for cyclooxygenase‐1 and cyclooxygenase‐2 in human tissues
O'Neill, G. P., & Ford-Hutchinson, A. W. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80263-t · Cited by 707
Riendeau, D., Percival, M. D., Brideau, C., Charleson, S., Dubé, D., Ethier, D., Falgueyret, J.-P., Friesen, R. W., Gordon, R., Greig, G., et al. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38776-2 · Cited by 460
Mechanism of Action of Acetaminophen: Is There a Cyclooxygenase 3?
Botting, R. M. (2000) · Clinical Infectious Diseases · doi:10.1086/317520 · Cited by 350
Ketorolac: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential
Buckley, M. M.-T., & Brogden, R. N. (1990) · Drugs · doi:10.2165/00003495-199039010-00008 · Cited by 348
A radioimmunoassay for 6-keto- prostaglandin F1α
Simon, J. A. (1978) · Prostaglandins · doi:10.1016/0090-6980(78)90122-3 · Cited by 317
Identification of a phorbol ester-repressible v-src-inducible gene.
Simmons, D. L., Levy, D. B., Yannoni, Y., & Erikson, R. L. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.4.1178 · Cited by 316
Self-citation
Research works printed but not linked: 3
- J Sambrook, D Russell Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Lab. Press, 3rd Ed., Plainview, NY, 2001).
- M A Moyad Semin Urol Oncol 19, 280–293 (2001).
- D Riendeau, M D Percival, C Brideau, S Charleson, D Dube, D Ethier, J P Falgueret, R W Friesen, R Gordon, G Greig, et al. J Pharmacol Exp Ther 296, 558–566 (2001).
Cited by
Items 101–145 of 145
Toussaint, K., Yang, X. C., Zielinski, M. A., Reigle, K. L., Sacavage, S. D., Nagar, S., & Raffa, R. B. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01143.x · Cited by 135
“However, COX-3 does not mediate antinociception in rats, COX-3 is not detected in humans, and the low expression level and kinetics make it is unlikely that COX-3 has clinical relevance for paracetamol’s mechanism of analgesic action (88).”
BackgroundInfluentialProstaglandins and sickness behavior: Old story, new insights
Pecchi, E., Dallaporta, M., Jean, A., Thirion, S., & Troadec, J.-D. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.02.040 · Cited by 135
De Caterina, R., & Massaro, M. (2005) · Journal of Membrane Biology · doi:10.1007/s00232-005-0783-2 · Cited by 130
Cerella, C., Sobolewski, C., Dicato, M., & Diederich, M. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.06.050 · Cited by 129
Cellular mechanisms of acetaminophen: role of cyclo‐oxygenase
Lucas, R., Warner, T. D., Vojnovic, I., & Mitchell, J. A. (2005) · The FASEB Journal · doi:10.1096/fj.04-2437fje · Cited by 128
“In cyclo-oxygenase-3 this signal peptide is not cleaved, and the protein is glycosylated and displays cyclo-oxygenase activity (2).”
BackgroundInfluentialCristino, L., Starowicz, K., De Petrocellis, L., Morishita, J., Ueda, N., Guglielmotti, V., & Di Marzo, V. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2007.11.047 · Cited by 115
Single dose oral paracetamol (acetaminophen) for postoperative pain
Barden, J., Edwards, J., Moore, A., & McQuay, H. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004602 · Cited by 113
Novel Aspects of Endothelium-Dependent Regulation of Vascular Tone
Villar, I. C., Francis, S., Webb, A., Hobbs, A. J., & Ahluwalia, A. (2006) · Kidney International · doi:10.1038/sj.ki.5001680 · Cited by 112
Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion
Rose, J. W., Hill, K. E., Watt, H. E., & Carlson, N. G. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.12.021 · Cited by 107
Ayoub, S. S., Botting, R. M., Goorha, S., Colville-Nash, P. R., Willoughby, D. A., & Ballou, L. R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404185101 · Cited by 104
COX-3: in the wrong frame in mind
Dinchuk, J. E., Liu, R. Q., & Trzaskos, J. M. (2003) · Immunology Letters · doi:10.1016/s0165-2478(02)00268-7 · Cited by 100
García-Bueno, B., Madrigal, J. L. M., Pérez-Nievas, B. G., & Leza, J. C. (2008) · Endocrinology · doi:10.1210/en.2007-0482 · Cited by 97
“Afterward the membranes were blocked in 10 mm Tris-buffered saline containing 0.1% Tween 20 and 5% skim milk, the membranes were, respectively, incubated with specific goat polyclonal COX-1 (raised against a epitope mapping near the C-terminus of COX-1 of human origin); COX-2 (peptide placed at the C terminus of COX-2…”
BackgroundInfluentialSang, N., Zhang, J., & Chen, C. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.105569 · Cited by 89
“Of the three isozymes of COX that have been identified (Vane et al. 1998; Bazan & Flower, 2002; Chandrasekharan et al. 2002), COX-2 is the focus of growing attention not only because it is inducible in inflammation, but also because it is involved in synaptic transmission and plasticity (Yamagata et al.”
BackgroundCloning and Characterization of Cyclooxygenase-1b (Putative Cyclooxygenase-3) in Rat
Snipes, J. A., Kis, B., Shelness, G. S., Hewett, J. A., & Busija, D. W. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.079533 · Cited by 82
Mallet, C., Desmeules, J., Pegahi, R., & Eschalier, A. (2023) · Journal of Pain Research · doi:10.2147/jpr.s393809 · Cited by 83
“COX-3 is an exon splice variant from COX-1 that was identified in the canine cerebral cortex and exhibited selective sensitivity to paracetamol.(34) However, further genomic and kinetic studies showed that a full-length, catalytically active form of COX-3 does not exist in humans(35,36) and that the COX-3 selective in…”
BackgroundAyoub, S. S., Colville-Nash, P. R., Willoughby, D. A., & Botting, R. M. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.03.061 · Cited by 79
Qin, N., Zhang, S.-P., Reitz, T. L., Mei, J. M., & Flores, C. M. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.090944 · Cited by 77
Progress in PET imaging of Neuroinflammation targeting COX-2 enzyme
Prabhakaran, J., Molotkov, A., Mintz, A., & Mann, J. J. (2021) · Molecules · doi:10.3390/molecules26113208 · Cited by 74
Bonnefont, J., Alloui, A., Chapuy, E., Clottes, E., & Eschalier, A. (2003) · Anesthesiology · doi:10.1097/00000542-200310000-00034 · Cited by 74
“new isoform preferentially expressed in cerebral cortex has been shown to be more sensitive to paracetamol.(27)”
BackgroundAcetaminophen reduces lipopolysaccharide-induced fever by inhibiting cyclooxygenase-2
Engström Ruud, L., Wilhelms, D. B., Eskilsson, A., Vasilache, A. M., Elander, L., Engblom, D., & Blomqvist, A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.012 · Cited by 70
A Comprehensive Review of Over the Counter Treatment for Chronic Low Back Pain
Peck, J., Urits, I., Peoples, S., Foster, L., Malla, A., Berger, A. A., Cornett, E. M., Kassem, H., Herman, J., Kaye, A. D., et al. (2021) · Pain and Therapy · doi:10.1007/s40122-020-00209-w · Cited by 65
Acetaminophen: Antipyretic or hypothermic in mice? In either case, PGHS-1b (COX-3) is irrelevant
Li, S., Dou, W., Tang, Y., Goorha, S., Ballou, L. R., & Blatteis, C. M. (2008) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2007.10.007 · Cited by 63
“To account, therefore, for its effect, it was suggested that another fevermediating PGE2 catalyst, the recently discovered AC-sensitive PGHS isoform PGHS-1b (COX-3), a splicing variant of PGHS-1 retaining intron-1, could be involved [17–19].”
BackgroundSaliba, S. W., Marcotegui, A. R., Fortwängler, E., Ditrich, J., Perazzo, J. C., Muñoz, E., de Oliveira, A. C. P., & Fiebich, B. L. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1014-3 · Cited by 62
“Acetaminophen produces a weak inhibition of COX, and it has been proposed that acetaminophen acts on COX-3, a brain-specific isoform of COX and slice variant of constitutive enzyme COX-1 [32, 33].”
COX‐3—a virtual pain target in humans?
Schwab, J. M., Beiter, T., Linder, J. U., Laufer, S., Schulz, J. E., Meyermann, R., & Schluesener, H. J. (2003) · The FASEB Journal · doi:10.1096/fj.03-0595lte · Cited by 59
“A long-sought molecule (1) was recently identified as acting independent of COX-1/-2 (2).”
BackgroundInfluentialGrim, T. W., Ghosh, S., Hsu, K.-L., Cravatt, B. F., Kinsey, S. G., & Lichtman, A. H. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.07.008 · Cited by 50
Ayoub, S. S., Yazid, S., & Flower, R. J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.166 · Cited by 48
“In addition, ANXA1 was shown to be constitutively expressed in CNS tissues (including spinal cord) of ANXA1þ /þ mice, as also previously demonstrated by Strijbos et al. (1990), and that expression was reduced dramatically in ANXA1 / mice.”
BackgroundInfluentialTurtle, E. J., Dear, J. W., & Webb, D. J. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12032 · Cited by 48
Paracetamol for Multimodal Analgesia
Freo, U. (2022) · Pain Management · doi:10.2217/pmt-2021-0116 · Cited by 46
Expanding the febrigenic role of cyclooxygenase-2 to the previously overlooked responses
Steiner, A. A., Rudaya, A. Y., Robbins, J. R., Dragic, A. S., Langenbach, R., & Romanovsky, A. A. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00371.2005 · Cited by 42
Cloning of cyclooxygenase-1b (putative COX-3) in mouse
Kis, B., Snipes, J. A., Gaspar, T., Lenzser, G., Tulbert, C. D., & Busija, D. W. (2006) · Inflammation Research · doi:10.1007/s00011-006-0083-z · Cited by 41
“Our COX-1b primer set distinguishes between COX-1 and COX-1b, and it also distinguishes between COX-1b and “partial” cyclooxygenases (PCOX-1a, PCOX-1b) because our antisense primer binds to exon 5 which is lacking in PCOXs [6].”
Bonnefont, J., Daulhac, L., Etienne, M., Chapuy, E., Mallet, C., Ouchchane, L., Deval, C., Courade, J.-P., Ferrara, M., Eschalier, A., et al. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.025775 · Cited by 39
Pharmacological hypotheses: Is acetaminophen selective in its cyclooxygenase inhibition?
Esh, C. J., Chrismas, B. C. R., Mauger, A. R., & Taylor, L. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.835 · Cited by 38
Timing of the effect of acetaminophen on body temperature in patients with acute ischemic stroke
Dippel, D. W. J., van Breda, E. J., van der Worp, H. B., van Gemert, H. M. A., Kappelle, L. J., Algra, A., & Koudstaal, P. J. (2003) · Neurology · doi:10.1212/01.wnl.0000080364.40229.0b · Cited by 37
Acetaminophen Use and Risk of Myocardial Infarction and Stroke in a Hypertensive Cohort
Fulton, R. L., Walters, M. R., Morton, R., Touyz, R. M., Dominiczak, A. F., Morrison, D. S., Padmanabhan, S., Meredith, P. A., McInnes, G. T., & Dawson, J. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04945 · Cited by 35
Acetaminophen use and change in blood pressure in a hypertensive population
Dawson, J., Fulton, R., McInnes, G. T., Morton, R., Morrison, D., Padmanabhan, S., Hewitt, J., Meredith, P., Muir, S., Dominiczak, A. F., et al. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328360f6f8 · Cited by 27
“Recent data suggest that acetaminophen acts through an indirect effect on the COX-2 enzyme [5,13] and perhaps on a central splice variant of this enzyme, COX-3 [6].”
BackgroundMicroglia as a cellular target of diclofenac therapy in Alzheimer’s disease
Stopschinski, B. E., Weideman, R. A., McMahan, D., Jacob, D. A., Little, B. B., Chiang, H.-S., Saez Calveras, N., & Stuve, O. (2023) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864231156674 · Cited by 26
Tortorici, V., Aponte, Y., Acevedo, H., Nogueira, L., & Vanegas, H. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06678.x · Cited by 23
“water and inhibits cyclooxygenase activity (Campos et al., 1999; Chandrasekharan et al., 2002).”
BackgroundMihalyi, A., Mutinda, K. C., Simsa, P., Debrock, S., Mwenda, J. M., & D’Hooghe, T. M. (2005) · Therapy · doi:10.2217/14750708.2.4.623 · Cited by 22
Ayoub, S. S., & Flower, R. J. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172609 · Cited by 19
Ayoub, S. S., Wood, E. G., Hassan, S.-U., & Bolton, C. (2011) · Inflammation Research · doi:10.1007/s00011-011-0352-3 · Cited by 19
Bashir, S., Elegunde, B., & Morgan, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113774 · Cited by 17
Opioid, cannabinoid CB1 and NOP receptors do not mediate APAP-induced hypothermia in rats
Corley, G., & Rawls, S. M. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.01.020 · Cited by 14
“One possibility is the APAP-sensitive PGHS isoform PGHS-1b (COX-3), a splicing variant of PGHS-1 retaining intron-1 (Simmons et al., 2000; Chandrasekharan et al., 2002; Ayoub et al., 2004).”
BackgroundAcetaminophen (Paracetamol) Induces Hypothermia During Acute Cold Stress
Foster, J., Mauger, A. R., Govus, A., Hewson, D., & Taylor, L. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0560-x · Cited by 13
Milani, G. P., Nicolini, G., Cananzi, M., Spiezia, L., & Vidal, E. (2026) · Children · doi:10.3390/children13010071 · Cited by 5
Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management
Nicolas, J., Leoni, M. L. G., Van Tran, Y., Van Phong, P., Farì, G., Puttini, P. S., Kaye, A. D., & Varrassi, G. (2026) · Current Pain and Headache Reports · doi:10.1007/s11916-026-01553-w
Metadata
- Authors
- Chandrasekharan, N. V., Dai, H., Roos, K. L. T., Evanson, N. K., Tomsik, J., Elton, T. S., & Simmons, D. L.
- Affiliations
- Brigham Young University (US)
- Corresponding author
- Simmons, Daniel L.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-09-19
- Volume
- 99
- Issue
- 21
- Pages
- 13926-13931
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC129799
- OpenAlex
- W2024289681
- Cited by
- 1,989
- References
- 41
- Citations by year
- 2026: 22 · 2025: 42 · 2024: 49 · 2023: 49 · 2022: 41 · 2021: 55 · 2020: 51 · 2019: 61 · 2018: 52 · 2017: 48 · 2016: 69 · 2015: 75 · 2014: 73 · 2013: 80 · 2012: 84
- FWCI
- 92.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Brigham Young University
- National Institutes of Health (5r01ar046688-03)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR46688)
- Division of Mathematical Sciences
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Keywords
- cyclooxygenase-1, paracetamol, analgesic-antipyretic drugs, nonsteroidal anti-inflammatory drugs, prostaglandin synthesis, intron 1, signal peptide, glycosylation, gene cloning, enzyme inhibition
- MeSH terms
- Acetaminophen, Animals, Aorta, Cerebral Cortex, Cloning, Molecular, Dogs, Humans, Isoenzymes, Membrane Proteins, Molecular Sequence Data, Prostaglandin-Endoperoxide Synthases, Recombinant Proteins, RNA, Messenger, Tissue Distribution, Genetic Variation, Molecular Structure, Cyclooxygenase Inhibitors, Analgesics, Non-Narcotic, Mice, Cyclooxygenase 1, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.